Desu H, Balthazard R, Daigneault A, Da Cal S, Klement W, Yu J
EBioMedicine. 2025; 112:105559.
PMID: 39837012
PMC: 11788784.
DOI: 10.1016/j.ebiom.2025.105559.
Jalilian M, Elhaie M, Sharifi M, Abedi I
BMJ Neurol Open. 2024; 6(2):e000788.
PMID: 39649079
PMC: 11624819.
DOI: 10.1136/bmjno-2024-000788.
Fouad G, Mabrouk M, El-Sayed S, Abdelhameed M, Rizk M, Beherei H
Biometals. 2024; 38(1):203-229.
PMID: 39543075
PMC: 11754386.
DOI: 10.1007/s10534-024-00648-4.
Fazazi M, Doss P, Pereira R, Fudge N, Regmi A, Joly-Beauparlant C
Nat Commun. 2024; 15(1):5404.
PMID: 38926356
PMC: 11208426.
DOI: 10.1038/s41467-024-49259-0.
Desu H, Sawicka K, Wuerch E, Kitchin V, Quandt J
Front Neurol. 2024; 15:1382468.
PMID: 38654736
PMC: 11035744.
DOI: 10.3389/fneur.2024.1382468.
Clinical characteristics and dynamics of disability progression in a cohort of patients with multiple sclerosis in Latvians.
Kalnina J, Trapina I, Sjakste N, Paramonova N
Neurol Sci. 2024; 45(7):3347-3358.
PMID: 38393441
PMC: 11176098.
DOI: 10.1007/s10072-024-07404-z.
Progression risk stratification with six-minute walk gait speed trajectory in multiple sclerosis.
Goldman M, Chen S, Motl R, Pearsall R, Oh U, Brenton J
Front Neurol. 2023; 14:1259413.
PMID: 37859654
PMC: 10582752.
DOI: 10.3389/fneur.2023.1259413.
ALCAM on human oligodendrocytes mediates CD4 T cell adhesion.
Jamann H, Desu H, Cui Q, Halaweh A, Tastet O, Klement W
Brain. 2023; 147(1):147-162.
PMID: 37640028
PMC: 10766241.
DOI: 10.1093/brain/awad286.
Impact of aging on treatment considerations for multiple sclerosis patients.
Macaron G, Larochelle C, Arbour N, Galmard M, Girard J, Prat A
Front Neurol. 2023; 14:1197212.
PMID: 37483447
PMC: 10361071.
DOI: 10.3389/fneur.2023.1197212.
Implications of immunometabolism for smouldering MS pathology and therapy.
Bittner S, Pape K, Klotz L, Zipp F
Nat Rev Neurol. 2023; 19(8):477-488.
PMID: 37430070
DOI: 10.1038/s41582-023-00839-6.
Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort.
Steffen F, Uphaus T, Ripfel N, Fleischer V, Schraad M, Gonzalez-Escamilla G
Neurol Neuroimmunol Neuroinflamm. 2022; 10(1).
PMID: 36411080
PMC: 9679887.
DOI: 10.1212/NXI.0000000000200055.
Chronic experimental autoimmune encephalomyelitis is an excellent model to study neuroaxonal degeneration in multiple sclerosis.
Voskuhl R, MacKenzie-Graham A
Front Mol Neurosci. 2022; 15:1024058.
PMID: 36340686
PMC: 9629273.
DOI: 10.3389/fnmol.2022.1024058.
Back to the Future: The Role of Infections in Psychopathology. Focus on OCD.
Della Vecchia A, Marazziti D
Clin Neuropsychiatry. 2022; 19(4):248-263.
PMID: 36101642
PMC: 9442856.
DOI: 10.36131/cnfioritieditore20220407.
Charting the proteome landscape in major psychiatric disorders: From biomarkers to biological pathways towards drug discovery.
Fernandes B, Dai Y, Jia P, Zhao Z
Eur Neuropsychopharmacol. 2022; 61:43-59.
PMID: 35763977
PMC: 9378550.
DOI: 10.1016/j.euroneuro.2022.06.001.
The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
Cohan S, Benedict R, Cree B, DeLuca J, Hua L, Chun J
CNS Drugs. 2022; 36(7):703-719.
PMID: 35725892
PMC: 9259525.
DOI: 10.1007/s40263-022-00927-z.
Obesity and the Brain.
Karczewski J, Zielinska A, Staszewski R, Eder P, Dobrowolska A, Souto E
Int J Mol Sci. 2022; 23(11).
PMID: 35682824
PMC: 9181303.
DOI: 10.3390/ijms23116145.
SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation.
MacDougall M, El-Hajj Sleiman J, Beauchemin P, Rangachari M
Front Immunol. 2022; 13:871276.
PMID: 35572514
PMC: 9102605.
DOI: 10.3389/fimmu.2022.871276.
Contact-Dependent Granzyme B-Mediated Cytotoxicity of Th17-Polarized Cells Toward Human Oligodendrocytes.
Jamann H, Cui Q, Desu H, Pernin F, Tastet O, Halaweh A
Front Immunol. 2022; 13:850616.
PMID: 35479072
PMC: 9035748.
DOI: 10.3389/fimmu.2022.850616.
Preventing disease progression in multiple sclerosis-insights from large real-world cohorts.
Engel S, Zipp F
Genome Med. 2022; 14(1):41.
PMID: 35440092
PMC: 9020060.
DOI: 10.1186/s13073-022-01044-8.
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Arnold D, Piani-Meier D, Bar-Or A, Benedict R, Cree B, Giovannoni G
Mult Scler. 2022; 28(10):1526-1540.
PMID: 35261318
PMC: 9315182.
DOI: 10.1177/13524585221076717.